Impact of Statin Use on Development of New-Onset Diabetes Mellitus in Asian Population

详细信息    查看全文

• 作者：Seung-Woon Rha ; MD ; PhD^a ; ^{swrha617@yahoo.co.kr" class="auth_mail" title="E-mail the corresponding author} ; Byoung Geol Choi ; BS^b ; Hong Seog Seo ; MD ; PhD^c ; Sang-Ho Park ; MD ; PhD^a ; Ji Young Park ; MD ; PhD^d ; Kang-Yin Chen ; MD ; PhD^e ; Yoonjee Park ; MD^a ; Se Yeon Choi ; BS^b ; Min-Suk Shim ; BS^a ; Ji Bak Kim ; MD^f ; Taeshik Park ; MD^g ; Joonhyung Park ; MD^h ; Jae Joong Lee ; MD^a ; Eun Jin Park ; MD^a ; Sung Hun Park ; MDⁱ ; Jah Yeon Choi ; MD^a ; Sunki Lee ; MD^a ; Jin Oh Na ; MD ; PhD^a ; Cheol Ung Choi ; MD ; PhD^a ; Hong Euy Lim ; MD ; PhD^a ; Jin Won Kim ; MD ; PhD^a ; Eung Ju Kim ; MD ; PhD^a ; Chang Gyu Park ; MD ; PhD^a ; Dong Joo Oh ; MD ; PhD^a
• 刊名：The American Journal of Cardiology
• 出版年：2016
• 出版时间：1 February 2016
• 年：2016
• 卷：117
• 期：3
• 页码：382-387
• 全文大小：230 K

文摘

There have been several reports showing that the statin use is associated with new-onset diabetes mellitus (DM). The aim of the present study was to evaluate the impact of chronic statin use on development of new-onset DM in a series of Asian population. The patients were retrospectively enrolled using the electronic database of Korea University Guro Hospital from January 2004 to February 2010. A total of 10,994 patients without a history of diabetes were analyzed. Baseline lipid profiles, fasting glucose, Hemoglobin (Hb) A1c, and glucose tolerance tests were measured in all patients before statin treatment. Included patients had HbA1c ≤5.7% and fasting glucose level ≤100 (mg/dl). The patients were divided into 2 groups according to the use of statins (the statin group, n = 2,324 patients and the nonstatin group, n = 8,670 patients). To adjust baseline potential confounders, a propensity score–matched analysis was performed using logistic regression model. After propensity score matching, 2 propensity-matched groups (1,699 pairs, n = 3,398, C statistic = 0.859) were generated and analyzed. After propensity score matching, baseline characteristics of both groups were balanced except that the statin group was older and had higher rate of coronary artery disease compared with the nonstatin group. During a 3-year follow-up, the statin group had higher incidence of new-onset DM compared with the nonstatin group (hazard ratio 1.99, 95% CI 1.36 to 2.92, p <0.001), but the statin group showed lower incidence of major adverse cerebral-cardiovascular events compared with the nonstatin group (hazard ratio 0.40, 95% CI 0.19 to 0.85, p <0.001). In the present study, although the use of statins was associated with higher rate of new-onset DM, it markedly improved 3-year cardiovascular outcomes in Asian population.